Chen Pei, Zhang Yu-Ling, Xue Bai, Xu Guo-Ying
Department of Basic Medicine, Jiangsu College of Nursing, Huai'an, China.
Department of Medical Technology, Jiangsu College of Nursing, Huai'an, China.
Front Oncol. 2021 Jan 8;10:562774. doi: 10.3389/fonc.2020.562774. eCollection 2020.
The prognostic value of caveolin-1 in prostate cancer remains uncertain. Hence, this meta-analysis was performed to evaluate the prognostic value of caveolin-1 in prostate cancer, as well as ascertain the relationship between caveolin-1 expression and clinicopathological characteristics of prostate cancer patients.
The PubMed, Embase, Chinese National Knowledge Infrastructure and Chinese Biology Medicine databases were electronically searched to retrieve published studies on caveolin-1 expression in prostate cancer. After study selection and data extraction, the meta-analysis was conducted using Review manager 5.3 software. Odds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect. Funnel plot was used to assess publication bias.
A total of ten studies were enrolled, which included 3976 cases of prostate cancer, 72 cases of high-grade intraepithelial neoplasia (HGPIN), and 157 normal controls. Results of the meta-analysis showed that the positive rate of caveolin-1 expression in prostate cancer was 18.28 times higher than that in normal control (OR= 18.28, 95% CI: 9.02-37.04, p<0.01), and 4.73 times higher than that in HGPIN (OR= 4.73, 95% CI: 2.38-9.42, p<0.01). The relationship between caveolin-1 and clinicopathological characteristics of prostate cancer showed that the differences in caveolin-1 expression in patients with prostate-specific antigen (PSA) >10 vs. ≤ 10 (OR=2.09, 95% CI: 1.35-3.22, p<0.01), differentiation degree low vs. medium/high (OR=2.74, 95% CI: 1.84-4.08, p<0.01), TNM stage T3+T4 vs. T1+T2 (OR=2.77, 95% CI: 1.78-4.29, p<0.01), and lymph node metastasis present vs. absent (OR=2.61, 95% CI: 1.84-3.69, p<0.01) were statistically significant. The correlation analysis between caveolin-1 and the survival time of patients with prostate cancer demonstrated that caveolin-1 was closely related to the prognosis of prostate cancer patients (HR=1.50, 95% CI: 1.28-1.76, p<0.01).
Caveolin-1 is overexpressed in prostate cancer, which can serve as a risk factor and adverse clinicopathological feature of prostate cancer. Caveolin-1 can also predict poor survival in prostate cancer patients after radical prostatectomy.
小窝蛋白-1在前列腺癌中的预后价值仍不确定。因此，进行本荟萃分析以评估小窝蛋白-1在前列腺癌中的预后价值，并确定小窝蛋白-1表达与前列腺癌患者临床病理特征之间的关系。
通过电子检索PubMed、Embase、中国知网和中国生物医学数据库，以获取已发表的关于前列腺癌中小窝蛋白-1表达的研究。在进行研究筛选和数据提取后，使用Review manager 5.3软件进行荟萃分析。采用比值比（OR）及95%置信区间（CI）来估计合并效应。采用漏斗图评估发表偏倚。
共纳入10项研究，包括3976例前列腺癌病例、72例高级别上皮内瘤变（HGPIN）和157例正常对照。荟萃分析结果显示，前列腺癌中小窝蛋白-1表达的阳性率比正常对照高18.28倍（OR = 18.28，95% CI：9.02 - 37.04，p < 0.01），比HGPIN高4.73倍（OR = 4.73，95% CI：2.38 - 9.42，p < 0.01）。小窝蛋白-1与前列腺癌临床病理特征之间的关系表明，前列腺特异性抗原（PSA）>10 vs.≤10的患者中小窝蛋白-1表达差异有统计学意义（OR = 2.09，95% CI：1.35 - 3.22，p < 0.01），低分化程度vs.中/高分化程度（OR = 2.74，95% CI：1.84 - 4.08，p < 0.01），TNM分期T3 + T4 vs. T1 + T2（OR = 2.77，95% CI：1.78 - 4.29，p < 0.01），以及有淋巴结转移vs.无淋巴结转移（OR = 2.61，95% CI：1.84 - 3.69，p < 0.01）。小窝蛋白-1与前列腺癌患者生存时间的相关性分析表明，小窝蛋白-1与前列腺癌患者的预后密切相关（HR = 1.50，95% CI：1.28 - 1.76，p < 0.01）。
小窝蛋白-1在前列腺癌中过表达，可作为前列腺癌的危险因素和不良临床病理特征。小窝蛋白-1还可预测前列腺癌患者根治性前列腺切除术后的不良生存情况。
